Market Summary
USD29.17+0.55
Market Closed1.92%
CRNX Stock Price
CRNX RSI Chart
CRNX Valuation
CRNX Price/Sales (Trailing)
CRNX Profitability
CRNX Fundamentals
CRNX Revenue
CRNX Earnings
Price Action
52 Week Range
31.00
(Low)(High)
Last 7 days
0.3%
Last 30 days
78.3%
Last 90 days
54.0%
Trailing 12 Months
43.7%
CRNX Financial Health
CRNX Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for CRNX
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-14 | Struthers Richard Scott | acquired | 19,100 | 1.91 | 10,000 | president & ceo |
2023-07-13 | Struthers Richard Scott | sold | -288,095 | 20.35 | -14,157 | president & ceo |
2023-07-12 | Struthers Richard Scott | sold | -231,128 | 20.17 | -11,459 | president & ceo |
2023-07-11 | Struthers Richard Scott | sold | -491,094 | 20.14 | -24,384 | president & ceo |
2023-06-20 | Wilson Marc | acquired | 185,600 | 9.28 | 20,000 | cfo |
2023-06-20 | Wilson Marc | sold | -617,403 | 19.9665 | -30,922 | cfo |
2023-06-16 | Vivaldi Coelho Rogerio | acquired | - | - | 6,000 | - |
2023-06-16 | Struthers Richard Scott | sold | -1,040,500 | 20.81 | -50,000 | president & ceo |
2023-06-16 | Okey Stephanie | acquired | - | - | 6,000 | - |
2023-06-16 | Nichols Weston | acquired | - | - | 6,000 | - |
Which funds bought or sold CRNX recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -45.23 | -22,007,700 | 35,083,800 | 1.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -3.27 | 72,212 | 917,867 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 382 | 35,432 | 43,461 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -27.17 | -142,000 | 635,000 | 0.01% |
2023-08-16 | Nuveen Asset Management, LLC | added | 176 | 4,187,090 | 6,184,090 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 18.19 | 2,725,150 | 11,079,500 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 42.44 | 297,710 | 795,313 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | 100,352 | 922,624 | -% |
2023-08-15 | NATIXIS ADVISORS, L.P. | added | 0.82 | 42,000 | 367,000 | -% |
2023-08-15 | EVENTIDE ASSET MANAGEMENT, LLC | unchanged | - | 852,145 | 7,834,520 | 0.13% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Crinetics Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 18, 2023 | point72 asset management, l.p. | 5.6% | 3,719,200 | SC 13G | |
| Feb 14, 2023 | braidwell lp | 6.45% | 3,469,674 | SC 13G | |
| Feb 14, 2023 | biotechnology value fund l p | 2.7% | 1,447,317 | SC 13G/A | |
| Feb 14, 2023 | orbimed advisors llc | 5.0% | 2,710,710 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 08, 2023 | driehaus capital management llc | 10.45% | 5,624,744 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 5.21% | 2,804,485 | SC 13G | |
| Jan 31, 2023 | blackrock inc. | 7.3% | 3,917,489 | SC 13G/A | |
| Apr 26, 2022 | perceptive advisors llc | 10.0% | 5,333,532 | SC 13D/A | |
| Apr 21, 2022 | perceptive advisors llc | 10.0% | 5,333,532 | SC 13D/A |
Recent SEC filings of Crinetics Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 18, 2023 | SC 13G | Major Ownership Report | |
| Sep 13, 2023 | 424B5 | Prospectus Filed | |
| Sep 13, 2023 | 8-K | Current Report | |
| Sep 11, 2023 | 424B5 | Prospectus Filed | |
| Sep 11, 2023 | 8-K | Current Report | |
| Aug 16, 2023 | 4 | Insider Trading | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 08, 2023 | 8-K | Current Report | |
| Jul 13, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 13, 2023 | 4 | Insider Trading |
Peers (Alternatives to Crinetics Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.23 | 4.28 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 29.9M | - | 1.35% | 3552.08% | -0.65 | - | - | -31.51% |
Crinetics Pharmaceuticals News
Returns for CRNX
Cumulative Returns on CRNX
-1.7%
5-Year Cumulative Returns
22.0%
3-Year Cumulative Returns
Risks for CRNX
What is the probability of a big loss on CRNX?
100%
Probability that Crinetics Pharmaceuticals stock will be more than 20% underwater in next one year
85.4%
Probability that Crinetics Pharmaceuticals stock will be more than 30% underwater in next one year.
53.9%
Probability that Crinetics Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does CRNX drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Crinetics Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Financials for Crinetics Pharmaceuticals
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
| Revenue | 12.8% | 4,834,000 | 4,285,000 | 4,737,000 | 5,370,667 | 7,140,000 | 12,524,000 | 1,078,000 | 735,000 | 392,000 | 897,000 | 897,000 | 1,193,000 | 1,653,000 | 1,696,000 | 2,353,000 | 2,428,000 | 2,175,000 | 2,267,000 | 2,442,000 | 2,071,400 | 1,700,800 |
| Operating Expenses | 5.6% | 196,817,000 | 186,318,000 | 172,619,000 | 156,320,000 | 140,215,000 | 122,820,000 | 108,780,000 | 75,024,000 | 68,768,000 | 66,051,000 | 62,467,000 | 55,025,000 | 49,702,000 | 42,586,000 | 35,581,000 | 31,138,000 | 23,955,000 | 18,351,000 | 14,486,000 | 11,172,000 | 10,857,333 |
| S&GA Expenses | 6.2% | 48,731,000 | 45,877,000 | 42,394,000 | 38,482,000 | 32,784,000 | 27,897,000 | 24,525,000 | 18,026,000 | 16,457,000 | 15,616,000 | 14,354,000 | 13,519,000 | 12,688,000 | 10,509,000 | 8,567,000 | 6,659,000 | 4,565,000 | 3,324,000 | 2,598,000 | 1,939,000 | 1,962,667 |
| R&D Expenses | 5.4% | 148,086,000 | 140,441,000 | 130,225,000 | 117,838,000 | 107,431,000 | 94,923,000 | 84,255,000 | 56,998,000 | 52,311,000 | 50,435,000 | 48,113,000 | 41,506,000 | 37,014,000 | 32,077,000 | 27,014,000 | 24,479,000 | 19,390,000 | 15,027,000 | 11,888,000 | 9,233,000 | 8,894,667 |
| EBITDA | - | - | - | - | - | -106,718,000 | -106,703,000 | -106,719,000 | -72,856,000 | -49,462,000 | -49,478,000 | -49,492,000 | -49,527,000 | -26,241,000 | -26,330,000 | -26,484,000 | - | - | - | - | - | - |
| EBITDA Margin | - | - | - | - | - | -14.95 | -8.52 | -99.00 | -1,026 | -126 | -55.16 | -55.18 | -41.51 | -15.87 | -15.52 | -11.26 | - | - | - | - | - | - |
| Interest Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8,000 | 10,000 |
| EBT Margin | - | - | - | - | - | -15.08 | -8.59 | -99.85 | -1,039 | -128 | -56.21 | -56.21 | -42.26 | -16.40 | -15.99 | -11.52 | - | - | - | - | - | - |
| Net Income | -4.9% | -183,890,000 | -175,286,000 | -163,918,000 | -149,721,000 | -135,647,000 | -119,367,000 | -107,641,000 | -73,812,000 | -66,720,000 | -62,830,000 | -58,766,000 | -50,422,000 | -44,368,000 | -37,526,000 | -30,667,000 | -27,115,000 | -21,141,000 | -15,935,000 | -12,015,000 | -9,157,000 | -8,848,000 |
| Net Income Margin | 100.0% | - | -40.91 | -34.60 | -27.88 | -19.00 | -9.53 | -99.85 | -1,039 | -170 | -70.04 | -65.51 | -42.26 | -26.84 | -22.13 | - | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -143,965,000 | -116,861,000 | -104,297,000 | -90,949,000 | -82,471,000 | -89,024,000 | -62,213,000 | -59,733,000 | -55,239,000 | -51,996,000 | -46,873,000 | -39,689,000 | - | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -6.6% | 293 | 314 | 352 | 385 | 422 | 333 | 351 | 209 | 217 | 164 | 183 | 200 | 217 | 124 | 130 | 143 | 155 | 167 | 171 | 177 | 75.00 |
| Current Assets | -6.7% | 285 | 305 | 345 | 378 | 416 | 328 | 345 | 204 | 211 | 158 | 177 | 194 | 211 | 117 | 123 | 135 | 148 | 159 | 167 | 171 | 70.00 |
| Cash Equivalents | -4.0% | 40.00 | 41.00 | 33.00 | 31.00 | 62.00 | 146 | 201 | 162 | 179 | 106 | 93.00 | 118 | 161 | 51.00 | 41.00 | 67.00 | 60.00 | 63.00 | 45.00 | 170 | 69.00 |
| Net PPE | -1.3% | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 |
| Liabilities | 16.2% | 39.00 | 34.00 | 36.00 | 34.00 | 36.00 | 30.00 | 19.00 | 16.00 | 15.00 | 14.00 | 15.00 | 13.00 | 14.00 | 15.00 | 13.00 | 13.00 | 13.00 | 14.00 | 11.00 | 9.00 | 7.00 |
| Current Liabilities | 23.9% | 33.00 | 26.00 | 28.00 | 25.00 | 26.00 | 20.00 | 16.00 | 12.00 | 12.00 | 10.00 | 10.00 | 9.00 | 10.00 | 11.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 6.00 | 6.00 |
| Shareholder's Equity | -9.4% | 254 | 280 | 316 | 351 | 386 | 303 | 332 | 194 | 201 | 149 | 169 | 187 | 203 | 108 | 117 | 130 | 142 | 152 | 160 | 168 | - |
| Retained Earnings | -10.5% | -536 | -485 | -439 | -394 | -352 | -309 | -275 | -244 | -216 | -190 | -167 | -146 | -127 | -111 | -93.80 | -79.25 | -64.82 | -52.40 | -43.38 | -34.88 | -27.30 |
| Additional Paid-In Capital | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 204 | 202 | 2.00 |
| Shares Outstanding | 1.3% | 55.00 | 54.00 | 54.00 | 54.00 | 53.00 | 48.00 | 48.00 | 38.00 | 37.00 | 33.00 | 33.00 | 30.00 | 31.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 12.00 | 20.00 | 2.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -12.5% | -160,139 | -142,380 | -115,205 | -102,897 | -90,091 | -82,064 | -88,588 | -81,627 | -73,958 | -69,864 | -62,027 | -59,536 | -55,139 | -51,852 | -46,381 | -38,943 | -31,029 | -22,811 | -19,459 | -15,961 | -12,711 |
| Share Based Compensation | 9.9% | 33,653 | 30,609 | 28,268 | 25,478 | 22,599 | 19,701 | 17,352 | 15,165 | 13,391 | 11,686 | 10,427 | 9,287 | 8,360 | 7,413 | 6,294 | 5,310 | 4,231 | 2,921 | 2,320 | 1,544 | 840 |
| Cashflow From Investing | 251.3% | 123,866 | -81,841 | -173,980 | -312,631 | -326,478 | -132,369 | -56,483 | 36,423 | 18,616 | 16,380 | 217 | -3,714 | 41,566 | 33,407 | 41,667 | -64,191 | -84,890 | -94,802 | -119,458 | -1,008 | -775 |
| Cashflow From Financing | -88.1% | 14,333 | 120,667 | 121,963 | 285,704 | 300,091 | 254,402 | 252,679 | 88,920 | 73,299 | 108,146 | 114,571 | 114,491 | 114,671 | 6,529 | 67.00 | 59.00 | 107,227 | 106,706 | 170,198 | 177,260 | 70,060 |
CRNX Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Revenues | $ 988 | $ 439 | $ 3,667 | $ 3,570 |
| Operating expenses: | ||||
| Research and development | 40,640 | 32,995 | 79,108 | 61,247 |
| General and administrative | 13,343 | 10,489 | 25,532 | 19,195 |
| Total operating expenses | 53,983 | 43,484 | 104,640 | 80,442 |
| Loss from operations | (52,995) | (43,045) | (100,973) | (76,872) |
| Other income (expense): | ||||
| Interest income | 2,107 | 720 | 4,145 | 913 |
| Other income (expense), net | (91) | (81) | (146) | (64) |
| Change in valuation of derivative asset | 0 | 31 | 0 | 31 |
| Total other income, net | 2,016 | 670 | 3,999 | 880 |
| Loss before equity method investment | (50,979) | (42,375) | (96,974) | (75,992) |
| Loss on equity method investment | 0 | 0 | 0 | (1,010) |
| Net loss | $ (50,979) | $ (42,375) | $ (96,974) | $ (77,002) |
| Net loss per share: | ||||
| Net loss per share - basic | $ (0.94) | $ (0.81) | $ (1.79) | $ (1.54) |
| Net loss per share - diluted | $ (0.94) | $ (0.81) | $ (1.79) | $ (1.54) |
| Weighted average shares - basic | 54,275 | 52,522 | 54,092 | 50,130 |
| Weighted average shares - diluted | 54,275 | 52,522 | 54,092 | 50,130 |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on investment securities | $ 809 | $ (1,427) | $ 2,226 | $ (3,237) |
| Comprehensive loss | $ (50,170) | $ (43,802) | $ (94,748) | $ (80,239) |
CRNX Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 39,553 | $ 32,672 |
| Investment securities | 224,976 | 301,753 |
| Prepaid expenses and other current assets | 20,281 | 10,759 |
| Total current assets | 284,810 | 345,184 |
| Property and equipment, net | 3,223 | 3,500 |
| Operating lease right-of-use asset | 1,253 | 1,486 |
| Derivative asset | 668 | 668 |
| Restricted cash | 1,300 | 1,301 |
| Other assets | 2,000 | 37 |
| Total assets | 293,254 | 352,176 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 20,825 | 15,351 |
| Accrued compensation and related expenses | 8,596 | 9,081 |
| Deferred revenue | 2,080 | 2,240 |
| Operating lease liability | 1,109 | 1,051 |
| Total current liabilities | 32,610 | 27,723 |
| Operating lease liability, non-current | 1,456 | 2,024 |
| Deferred revenue, non-current | 5,072 | 6,101 |
| Total liabilities | 39,138 | 35,848 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par; 10,000 shares authorized; no shares issued or outstanding on June 30, 2023 or December 31, 2022 | 0 | 0 |
| Common stock and paid-in capital, $0.001 par; 200,000 shares authorized; 54,682 shares issued and outstanding on June 30, 2023; 53,877 shares issued and outstanding on December 31, 2022 | 791,968 | 759,432 |
| Accumulated other comprehensive loss | (1,705) | (3,931) |
| Accumulated deficit | (536,147) | (439,173) |
| Total stockholders’ equity | 254,116 | 316,328 |
| Total liabilities and stockholders’ equity | $ 293,254 | $ 352,176 |
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.